HIV vaccine triggers broadly neutralizing antibodies in 44% of primates

A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists and IAVI has the potential to protect humans from developing HIV infection and AIDS. This HIV ...
News-Medical.Net

New HIV vaccine successfully generates broadly neutralizing antibodies in primates

A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists, and IAVI has the ...
BioProcess International

Cell- and Virus-Bank Characterization in Product Development: A Risk-Based, Phase-Appropriate Framework for Quality Control

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...
The Manila Times

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to dise ...
BMJ Global Health

Enhancing malaria-in-pregnancy monitoring: stakeholder experiences and data integration into the BornFyne-PNMS digital platform in Cameroon

Malaria in pregnancy (MiP) is a significant public health concern in high-burden malaria countries and a key predictor of ...